Normal view MARC view ISBD view

Roflumilast--a phosphodiesterase-4 inhibitor licensed for add-on therapy in severe COPD.

Taegtmeyer, Anne B

Roflumilast--a phosphodiesterase-4 inhibitor licensed for add-on therapy in severe COPD. [electronic resource] - Swiss medical weekly 2012 - w13628 p. digital

Publication Type: Journal Article; Review

ISSN: 1424-3997

Standard No.: 10.4414/smw.2012.13628 doi

Subjects--Topical Terms:
Aminopyridines--adverse effects
Benzamides--adverse effects
Cyclopropanes--adverse effects
Drug Interactions
Drug Therapy, Combination
Humans
Phosphodiesterase 4 Inhibitors--adverse effects
Pulmonary Disease, Chronic Obstructive--drug therapy
Severity of Illness Index

Print
Cite
Add to your cart (remove)
Save record
BIBTEX Dublin Core MARCXML MARC (non-Unicode/MARC-8) MARC (Unicode/UTF-8) MARC (Unicode/UTF-8, Standard) MODS (XML) RIS ISBD
More searches

Search for this title in:
Other Libraries (WorldCat) Other Databases (Google Scholar) Online Stores (Bookfinder.com) Open Library (openlibrary.org)